GOALS Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and can be fatal. In the severe form of the disease complement activation causes red blood cells to be broken down in the bloodstream. At present no therapies for IMHA target this complement activation. We have confirmed that an FDA licensed formulation of C₁-INH is safe for dogs and effectively inhibits canine complement mediated hemolysis. We hope this will translate into a beneficial effect in dogs with intravascular red cell breakdown due to IMHA. In this trial, we aim to assess the efficacy of C₁-INH for management of intravascular IMHA.

ELIGIBILITY Dogs presenting to the Cornell University Hospital for Animals for intravascular IMHA

COMPENSATION Your dog will benefit from the provision of diagnostic testing and follow-up monitoring at zero cost to you. The drug or placebo will be provided free of charge. Any tests or procedures unrelated to the study will be your responsibility.

OWNER RESPONSIBILITIES If you agree to let your dog participate in this study, your dog will receive the same diagnostic tests and treatments as for any other dog with this disease and will receive standard of care therapies. In addition, your dog will be randomly assigned to receive either an infusion of C₁-INH or a saline placebo. We will perform daily blood sampling on your dog for up to 5 days or when he/she leaves the hospital (whichever is sooner).

Principal Investigators
Robert Goggs, BVSc, DACVECC, DECVECC, PhD, MRCVS

Contact Information
(607) 253-3060 vet-research@cornell.edu